ArticleUpdates in surgery2026
Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world retrospective cohort study of three conversion therapy regimens for unresectable locally advanced pancreatic cancer: a single-center 5-year analysis focused on conversion resection rate and survival outcomes.Translational cancer research · 2026Article
- Comment on "Exploration of ERK/Myc regulating ribosomal biosynthesis and promoting ALPPS-related liver regeneration".Updates in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemotherapy (NAC) is increasingly used for patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC). However, its impact on survival after radical surgery with vascular resection remains unclear. This retrospective cohort study investigates the survival benefits of NAC and identifies key predictive factors. We analyzed data from a single-center cohort of patients between January 1, 2012, and December 31, 2022. Among 106 patients studied, thirty-seven underwent upfront surgery (UPS) and sixty-nine received NAC followed by surgery. We compared demographic, surgical, and pathological outcomes, using Kaplan-Meier analysis and Cox regression for survival analysis. The NAC group comprised a higher proportion of stage III patients and displayed substantial reductions in tumor size and lymph node metastasis. NAC improved overall survival (OS) (34.4 months vs. 22.0 months, p = 0.0038) and progression-free survival (PFS) (17.2 months vs. 7.1 months, p < 0.0001) compared to UPS. CA19-9 normalization, pathological lymph node status and tumor size, tumor regression grade 0-1 and adjuvant therapy were significant predictors of better OS. Age over 60 years, lack of CA199 normalization, and pathological N2 were significant risks factors of PFS. NAC is associated with improved survival outcomes in BRPC and LAPC patients undergoing radical surgery with vascular resection. Key factors influencing survival include CA19-9 normalization and tumor response to therapy. Further prospective studies are needed to confirm these findings.
Indexed as
Identifiers
42207486What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.